Table of Contents

HK J Paediatr (New Series)
Vol 19. No. 2, 2014

HK J Paediatr (New Series) 2014;19:63-70

Original Article

Detection and Clinical Significance of a Potential Mediator of Airway Remodelling in Preschool Wheezy Children
對學齡前期喘息患兒氣道重塑的潛在調節因子進行檢測及其臨床意義

YY Zhang, HZ Xu, XE Bao, SX Li, YS Wang, Y Chen, ZM Chen


Abstract

Purpose: To detect levels of matrix metalloproteinase (MMP)-9, tissue inhibitors of metalloproteinase (TIMP)-1 and transforming growth factor beta 1 (TGF-β1), and analysis the relationship among wheezing and airway remodelling-associated factors. Methods: The levels of MMP-9, TIMP-1 and TGF-β1 were detected by enzyme-linked immunosorbent assay. Samples of blood and nasopharyngeal aspirates were analysed for pathogens. Meanwhile, levels of immunoglobulin E (IgE) and percentage of eosinophils were measured. Findings: Serum levels of MMP-9 were much higher in wheezy children than in controls (p<0.05) while the level of TIMP-1 and TGF-β1 between the wheezy and control had no significant differences (p>0.05). No significant effects of recurrent wheezing, pathogen infection, IgE level or asthma high risk factors on serum level of MMP-9 were observed (p>0.05). Conclusion: We found that serum MMP-9 levels were higher in wheezy children, indicating a possibility for airway remodelling in wheezy children. However, recurrent wheezing, pathogen infection and hereditary backgrounds had no effect on the serum level of MMP-9.

目的:檢測基質金屬蛋白酶(MMP)-9,基質金屬蛋白酶抑制物(TIMP)-1和轉化生長因子b1(TGF-b1)的組織抑製劑,以及分析之間的喘息和氣道重塑相關因素的關係。方法:用ELISA法檢測MMP-9和TIMP -1和TGF-β1的水平。血樣本和鼻咽抽吸物進行了病原體分析。同時,對免疫球蛋白E(IgE)的水平和嗜酸性粒細胞百分比進行測定。結果:喘息患兒MMP-9的血清水平明顯高於對照組(p<0.05),而與TIMP- 1和TGF-β1水平無顯著統計學差異(p>0.05)。反覆喘息、病原體感染、IgE的水平或哮喘的高危因素,對MMP -9的血清水平沒有顯著影響(p>0.05)。結論:我們發現喘息患兒的血清MMP- 9水平較高,這表明喘息患兒可能發生氣道重塑。然而,反覆喘息、病原體感染和遺傳因素對MMP-9的血清水平沒有影響。

Keyword : Airway remodelling; MMP-9; TGF-β1; TIMP-1; Wheezing

關鍵詞:氣道重塑、MMP-9、TGF-β1、TIMP- 1、喘息

 
 

This web site is sponsored by Johnson & Johnson (HK) Ltd.
©2022 Hong Kong Journal of Paediatrics. All rights reserved. Developed and maintained by Medcom Ltd.